Lansoprazole 30mg orodispersible tablets

Држава: Велика Британија

Језик: Енглески

Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)

Активни састојак:

Lansoprazole

Доступно од:

DE Pharmaceuticals

АТЦ код:

A02BC03

INN (Међународно име):

Lansoprazole

Дозирање:

30mg

Фармацеутски облик:

Orodispersible tablet

Пут администрације:

Oral

Класа:

No Controlled Drug Status

Тип рецептора:

Valid as a prescribable product

Резиме производа:

BNF: 01030500

Информативни летак

V028
Package leaflet: Information for the patient
Lansoprazole 30 mg orodispersible tablets
lansoprazole
Read all of this leaflet carefully before you start taking this
medicine because it
contains important information for you.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may
harm them, even if their signs of illness are the same as yours.
-
If you get any side effects talk to your doctor or pharmacist. This
includes any
possible side effects not listed in this leaflet. See section 4.
What is in this leaflet:
1. What Lansoprazole is and what it is used for
2. What you need to know before you take Lansoprazole
3. How to take Lansoprazole
4. Possible side effects
5. How to store Lansoprazole
6. Contents of the pack and other information
1.
What Lansoprazole is and what it is used for
The active ingredient in Lansoprazole is lansoprazole, which is a
proton pump inhibitor.
Proton pump inhibitors reduce the amount of acid that your stomach
makes.
Your doctor may prescribe Lansoprazole for the following indications:
-
Treatment of duodenal and stomach ulcer
-
Treatment of inflammation in your oesophagus (reflux oesophagitis)
-
Prevention of reflux oesophagitis
-
Treatment of heartburn and acid regurgitation
-
Treatment of infections caused by the bacteria Helicobacter pylori
when given in
combination with antibiotic therapy
-
Treatment or prevention of duodenal or stomach ulcer in patients
requiring continued
NSAID treatment (NSAID treatment is used against pain or inflammation)
-
Treatment of Zollinger-Ellison syndrome.
Your doctor may have prescribed Lansoprazole for another indication or
with a dose
different from that which is written in this information leaflet.
Please follow your doctor’s
instructions for taking your medicine.
You must talk to a doctor if you do not feel better or if you feel
worse after 14 days.
2.
What you need to know before you take La

Карактеристике производа

OBJECT 1
LANSOPRAZOLE 30MG ORODISPERSIBLE
TABLETS
Summary of Product Characteristics Updated 02-Apr-2019 | Lupin
Healthcare (UK) Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
Lansoprazole 30mg Orodispersible Tablets
2. Qualitative and quantitative composition
Each orodispersible tablet contains 30 mg of lansoprazole
Excipient(s) with known effect:
Each orodispersible tablet contains 10.50 mg of aspartame
For a full list of excipients, see section 6.1.
3. Pharmaceutical form
Orodispersible tablet.
White to yellowish white uncoated tablets, speckled with orange to
dark brown pellets, debossed with “30”
on one side of the tablet and plain on the other side.
4. Clinical particulars
4.1 Therapeutic indications
• Treatment of duodenal and gastric ulcer
• Treatment of reflux oesophagitis
• Prophylaxis of reflux oesophagitis
• Eradication of _Helicobacter pylori_ (_H. pylori_) concurrently
given with appropriate antibiotic therapy for
treatment of _H.pylori_-as